

Loredana Urso

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2301279/publications.pdf>

Version: 2024-02-01

38
papers

1,029
citations

430442

18
h-index

414034

32
g-index

38
all docs

38
docs citations

38
times ranked

1674
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial. <i>Clinical Cancer Research</i> , 2022, 28, 308-317.	3.2	36
2	mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells. <i>Redox Biology</i> , 2022, 51, 102268.	3.9	14
3	ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 625636.	1.3	8
4	P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment. <i>Frontiers in Oncology</i> , 2021, 11, 653497.	1.3	8
5	Detection of circulating immunosuppressive cytokines in malignant pleural mesothelioma patients for prognostic stratification. <i>Cytokine</i> , 2021, 146, 155622.	1.4	4
6	Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. <i>Clinical Lung Cancer</i> , 2020, 21, 1-14.e3.	1.1	19
7	Metabolic rewiring and redox alterations in malignant pleural mesothelioma. <i>British Journal of Cancer</i> , 2020, 122, 52-61.	2.9	22
8	Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 564915.	1.3	7
9	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. <i>Lancet Oncology</i> , The, 2020, 21, 1455-1464.	5.1	52
10	PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. <i>Clinical Cancer Research</i> , 2020, 26, 5843-5851.	3.2	17
11	Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives. <i>Frontiers in Oncology</i> , 2019, 9, 740.	1.3	20
12	De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study. <i>Annals of Oncology</i> , 2019, 30, 921-926.	0.6	64
13	PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+ breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 544-544.	0.8	6
14	Targeted Therapies in Mesothelioma. , 2019, , 243-259.		0
15	Clinical features and progression pattern of T790M+ compared with T790M-EGFR mutant NSCLC. <i>Journal of Clinical Oncology</i> , 2019, 37, e20612-e20612.	0.8	0
16	Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical pathological features and intratumor heterogeneity over time. <i>Annals of Oncology</i> , 2018, 29, 1258-1265.	0.6	75
17	Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists. <i>Oncotarget</i> , 2017, 8, 44232-44241.	0.8	12
18	211P: Inflammatory cells characterization and localization in malignant pleural mesothelioma (MPM) tissue samples: Correlation with histologic subtype and prognosis. <i>Journal of Thoracic Oncology</i> , 2016, 11, S148.	0.5	1

#	ARTICLE	IF	CITATIONS
19	Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 220-230.	2.0	43
20	MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data. <i>Oncotarget</i> , 2015, 6, 42053-42066.	0.8	20
21	Epirubicin plus paclitaxel regimen as second-line treatment of patients with small-cell lung cancer. <i>Anticancer Research</i> , 2015, 35, 2183-9.	0.5	2
22	Synergistic Antitumor Activity of Recombinant Human Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) in Combination with Carboplatin and Pemetrexed in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1008-1017.	0.5	9
23	Clinicopathologic features of patients with malignant mesothelioma in a multicenter, retrospective study.. <i>Journal of Clinical Oncology</i> , 2014, 32, e18544-e18544.	0.8	0
24	Effects of Sulfonylureas on Tumor Growth: A Review of the Literature. <i>Oncologist</i> , 2013, 18, 1118-1125.	1.9	48
25	Epigenetic Regulation of miR-212 Expression in Lung Cancer. <i>PLoS ONE</i> , 2011, 6, e27722.	1.1	75
26	Effects of cisplatin on matrix metalloproteinase-2 in transformed thyroid cells. <i>Biochemical Pharmacology</i> , 2010, 79, 810-816.	2.0	10
27	Sublethal concentrations of the platinum(II) complex [Pt(O,O- <i>acac</i>)(<i>3-acac</i>)(DMS)] alter the motility and induce anoikis in MCF-7 cells. <i>British Journal of Pharmacology</i> , 2010, 160, 1362-1377.	2.7	36
28	miR-212 Increases Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Sensitivity in Non-Small Cell Lung Cancer by Targeting the Antiapoptotic Protein PED. <i>Cancer Research</i> , 2010, 70, 3638-3646.	0.4	143
29	Cisplatin Reduces Endothelial Cell Migration Via Regulation of Type 2-Matrix Metalloproteinase Activity. <i>Cellular Physiology and Biochemistry</i> , 2009, 23, 441-448.	1.1	32
30	Functions of epidermal growth factor receptor in cisplatin response of thyroid cells. <i>Biochemical Pharmacology</i> , 2009, 77, 979-992.	2.0	14
31	Antiapoptotic effects of protein kinase C δ and c-fos in cisplatin-treated thyroid cells. <i>British Journal of Pharmacology</i> , 2009, 156, 751-763.	2.7	17
32	Angiotensin II induces MMP 2 activity via FAK/JNK pathway in human endothelial cells. <i>Biochemical and Biophysical Research Communications</i> , 2009, 380, 769-774.	1.0	35
33	PKC μ -dependent cytosol-to-membrane translocation of pendrin in rat thyroid PC Cl3 cells. <i>Journal of Cellular Physiology</i> , 2008, 217, 103-112.	2.0	28
34	[Pt(O,O- <i>acac</i>)(<i>3-acac</i>)(DMS)], a new Pt compound exerting fast cytotoxicity in MCF-7 breast cancer cells via the mitochondrial apoptotic pathway. <i>British Journal of Pharmacology</i> , 2008, 153, 34-49.	2.7	68
35	[Pt(O,O- <i>acac</i>)(<i>3-acac</i>)(DMS)], a new Pt compound exerting fast cytotoxicity in MCF-7 breast cancer cells via the mitochondrial apoptotic pathway. <i>British Journal of Pharmacology</i> , 2008, 153, 175-175.	2.7	11
36	New platinum(II) complexes containing both an O,O-chelated acetylacetonate ligand and a sulfur ligand in the platinum coordination sphere induce apoptosis in HeLa cervical carcinoma cells. <i>Biochemical Pharmacology</i> , 2007, 74, 28-40.	2.0	45

#	ARTICLE	IF	CITATIONS
37	Differential response of normal, dedifferentiated and transformed thyroid cell lines to cisplatin treatment. <i>Biochemical Pharmacology</i> , 2005, 71, 50-60.	2.0	14
38	Differential functions of PKC- δ and PKC- ϵ in cisplatin response of normal and transformed thyroid cells. <i>Biochemical and Biophysical Research Communications</i> , 2005, 337, 297-305.	1.0	14